ReviewTherapeutic advances in musculoskeletal disease2021
Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review.
Review in Therapeutic advances in musculoskeletal disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Evaluation of the Synovial Effects of Biological and Targeted Synthetic DMARDs in Patients with Psoriatic Arthritis: A Systematic Literature Review and Meta-Analysis.International journal of molecular sciences · 2023Pooled it
- Predicting clinical response in psoriatic arthritis through integrative analysis of transcriptomics and proteomics.Arthritis research & therapy · 2026Trial
- The development of a clinical prediction model for response to methotrexate, tofacitinib, and etanercept in patients with Psoriatic Arthritis.Arthritis research & therapy · 2025Trial
- Multi-omics profiling of chronic immune-mediated skin diseases: SKINERGY protocol and strategic evaluation.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Observational
- Article
- Exploring biomarkers for treatment response in psoriatic arthritis: a focus on multi-omics technologies.The pharmacogenomics journal · 2026Review
- From Convenience to Clinical Efficacy: Selective TYK2 Inhibition in Psoriasis and the Evolving Role of Next-Generation Oral Targeted Therapies.Pharmaceutics · 2026Review
- Predicting comorbidities in psoriasis using TCM constitution and multimodal data: a prospective cohort study protocol.Frontiers in medicine · 2026Article
- Sex differences in serum proteomic profiles in psoriatic arthritis.Rheumatology (Oxford, England) · 2025Article
- Navigating the Journey in Psoriatic Arthritis: Matching the Right Patient, the Right Drug, and the Right Time.Journal of clinical medicine · 2025Article
- The Phenomenon of Anti-Drug Antibodies in Psoriasis: Mechanisms, Clinical Impact, and Therapeutic Strategies.International journal of molecular sciences · 2025Review
- Tracking inflammation status for improving patient prognosis: A review of current methods, unmet clinical needs and opportunities.Biotechnology advances · 2025Review
- Association of skin microbiome with interleukin-23 in patients with plaque psoriasis.Postepy dermatologii i alergologii · 2025Article
- Navigating Psoriatic Arthritis: Treatment Pathways and Patient-Specific Strategies for Improved Outcomes.Drugs · 2025Review
- Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials.Rheumatology and therapy · 2024Article
- Plasma Cytokines for the Prediction of the Effectiveness of TNFα Inhibitors Etanercept, Infliximab, and Adalimumab in the Treatment of Psoriasis.Journal of clinical medicine · 2024Article
- Article
- State of the Art Review on the Treatment of Psoriatic Disease.Mediterranean journal of rheumatology · 2024Review
- Prevalence of metabolic syndrome and chronic inflammation in psoriasis before and after biologic therapy: a prospective study.Medicine and pharmacy reports · 2023Article
- Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Trials.ACR open rheumatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
aimsThe ability to predict response to treatment remains a key unmet need in psoriatic disease. We conducted a systematic review of studies relating to biomarkers associated with response to treatment in either psoriasis vulgaris (PsV) or psoriatic arthritis (PsA).
methodsA search was conducted in PubMed, Embase and the Cochrane library from their inception to 2 September 2020, and conference proceedings from four major rheumatology conferences. Original research articles studying pre-treatment biomarker levels associated with subsequent response to pharmacologic treatment in either PsV or PsA were included.
resultsA total of 765 articles were retrieved and after review, 44 articles (22 relating to PsV and 22 to PsA) met the systematic review's eligibility criteria. One study examined the response to methotrexate, one the response to tofacitinib and all the other studies to biologic disease-modifying antirheumatic drugs (DMARDs). Whilst several studies examined the
conclusionSeveral studies have identified biomarkers associated with subsequent response to treatment in psoriatic disease. However, due to the different types of biomarkers, treatments and outcome measures used, firm conclusions cannot be drawn. Further validation is needed before any of these biomarkers translate to clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.